Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B.

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

A scientist in a white lab coat working at a bench with biopharmaceutical equipment.

The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 mg and 3.2 log10 IU/mL at 400 mg, with additional declines in HBV RNA. The lower dose achieved saturated inhibition of viral replication, while the higher dose may enhance suppression of cccDNA formation, a key viral reservoir.

The drug was well-tolerated, with no serious adverse events and pharmacokinetics supporting once-daily oral dosing. These results activate a licensing decision for Gilead Sciences, which holds rights to further develop ABI-4334.

Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotech focused on small-molecule therapies for serious viral infections. Its pipeline includes candidates for hepatitis B, hepatitis delta, herpesviruses, and transplant-related infections. The company collaborates with Gilead Sciences to advance next-generation antiviral treatments.

While we acknowledge the potential of ASMB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ASMB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.